267 related articles for article (PubMed ID: 20515941)
1. Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
[TBL] [Abstract][Full Text] [Related]
3. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
[TBL] [Abstract][Full Text] [Related]
4. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
5. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Gril B; Palmieri D; Qian Y; Anwar T; Ileva L; Bernardo M; Choyke P; Liewehr DJ; Steinberg SM; Steeg PS
PLoS One; 2011; 6(10):e25625. PubMed ID: 21998674
[TBL] [Abstract][Full Text] [Related]
6. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Hamberg P; Verweij J; Sleijfer S
Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
[TBL] [Abstract][Full Text] [Related]
7. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
8. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Jain RK; Tong RT; Munn LL
Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J; Mortezaee K
Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
[TBL] [Abstract][Full Text] [Related]
12. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
KÅ‚osowska-Wardega A; Hasumi Y; Burmakin M; Ahgren A; Stuhr L; Moen I; Reed RK; Rubin K; Hellberg C; Heldin CH
PLoS One; 2009 Dec; 4(12):e8149. PubMed ID: 19997591
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Gremonprez F; Descamps B; Izmer A; Vanhove C; Vanhaecke F; De Wever O; Ceelen W
Oncotarget; 2015 Oct; 6(30):29889-900. PubMed ID: 26375674
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Zhu XD; Zhang JB; Fan PL; Xiong YQ; Zhuang PY; Zhang W; Xu HX; Gao DM; Kong LQ; Wang L; Wu WZ; Tang ZY; Ding H; Sun HC
BMC Cancer; 2011 Jan; 11():28. PubMed ID: 21251271
[TBL] [Abstract][Full Text] [Related]
15. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.
Ohta M; Kawabata T; Yamamoto M; Tanaka T; Kikuchi H; Hiramatsu Y; Kamiya K; Baba M; Konno H
Surg Today; 2009; 39(12):1046-53. PubMed ID: 19997799
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts.
Zheng X; Goins BA; Cameron IL; Santoyo C; Bao A; Frohlich VC; Fullerton GD
Cancer Chemother Pharmacol; 2011 Jan; 67(1):173-82. PubMed ID: 20306263
[TBL] [Abstract][Full Text] [Related]
17. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
18. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit.
Iwase T; Oveson BC; Hashida N; Lima e Silva R; Shen J; Krauss AH; Gale DC; Adamson P; Campochiaro PA
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):503-11. PubMed ID: 23169884
[TBL] [Abstract][Full Text] [Related]
19. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Keir ST; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 Sep; 59(3):586-8. PubMed ID: 22190407
[TBL] [Abstract][Full Text] [Related]
20. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]